Prognostic value of multiple immune inflammatory markers in diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with variable prognoses.
• Identifying reliable prognostic markers is crucial for tailoring treatment strategies and improving patient outcomes.

Purpose of the Study:

• To evaluate the prognostic significance of multiple immune-inflammatory indicators in patients with DLBCL.
• To develop a predictive model for DLBCL prognosis using these indicators.

Main Methods:

• Retrospective analysis of clinical data from 175 DLBCL patients.
• Calculation and analysis of lymphocytes-to-beads ratio (LMR), neutrophils-to-lymphocytes ratio (NLR), and platelets-to-lymphocytes ratio (PLR).
• Utilized ROC curves, Kaplan-Meier survival analysis, Cox regression, and nomogram construction for prognostic assessment.

Main Results:

• Optimal cut-off values were determined for neutrophil count, LMR, C-reactive protein (CRP), NLR, monocyte count, and PLR.
• Patients with lower neutrophil counts, higher LMR, lower CRP, lower NLR, lower monocyte counts, and lower PLR exhibited better survival rates.
• The developed nomogram demonstrated high accuracy (AUC 0.962 and 0.952) in predicting DLBCL prognosis in both training and test sets.

Conclusions:

• Neutrophil count, NLR, and PLR, alongside the IPI score, are significant risk factors influencing DLBCL prognosis.
• A combined predictive model incorporating IPI score, neutrophil count, NLR, and PLR enhances prognostic accuracy for DLBCL.
• This model can serve as a valuable clinical tool for predicting DLBCL prognosis and guiding patient management.